RACQUEL GRADNEY: Open Payments
NPI 1699253401 · OPELOUSAS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$629 in 29 payments from 12 companies in 2025. Trend: 2023 $416 · 2024 $784 · 2025 $629
Food & beverage: $629
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $190 |
| Lilly USA, LLC | 4 | $76 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $70 |
| Axsome Therapeutics, Inc. | 3 | $67 |
| Phathom Pharmaceuticals, Inc. | 5 | $51 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| AstraZeneca Pharmaceuticals LP | 1 | $22 |
| ABBVIE INC. | 1 | $20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $17 |
Products named: Ozempic, MOUNJARO, CAPLYTA, Auvelity, VOQUEZNA, XIFAXAN, TRINTELLIX, FARXIGA.
Industry payments across LA — which companies pay providers there.
